Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Hydrochloride Liposome Injection (II) in Metastatic Pancreatic Cancer
NCT07238283Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan, sponsored by Hengrui. Started Dec 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecan
Beyond the preview
Go deeper on NCT07238283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238283.